首页> 外文期刊>Frontiers in Pharmacology >Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
【24h】

Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration

机译:静脉给药后比格犬血浆中风神经保护剂Neurounina-1的LC-MS / MS方法的开发,验证和药代动力学参数的确定

获取原文
           

摘要

Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na ~(+)/Ca ~(2+) exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 μL) by liquid-liquid extraction using acetonitrile (100 μL). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 & 83 and m/z 275 & 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm × 4.6 mm × 5 μm) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1–500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs ( n = 5). The mean AUC _(0-tlast) values were 26.10, 115.81, and 257.28 ng ~(?)h/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t _(1/2) of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range.
机译:Neurounina-1 [化学名称:7-硝基-5-苯基-1-(吡咯烷-1-基甲基)-1H-苯并[e] [1,4]二氮杂-2-2(3H)-是一种新化合物通过增加Na〜(+)/ Ca〜(2+)交换子(NCX)亚型NCX1和NCX2的活性,在卒中和新生儿缺氧中具有相关的神经保护作用。这项研究首次显示了液相色谱-串联质谱(LC-MS / MS)分析灵敏的选择性方法在比格犬血浆中神经氨酸-1分析方法的开发和验证。样品制备包括使用乙腈(100μL)通过液-液萃取从血浆(50μL)中萃取分析物和内标(IS)(罗哌卡因)。进行选定的正离子反应监测模式,产物离子跃迁的前体m / z 365 83和m / z 275& 126个样品用于测量Neurounina-1和罗哌卡因的衍生物。使用Phenomenex C18 Luna(150 mm×4.6 mm×5μm)分析柱进行色谱分离,该色谱柱的等度流动相为甲醇/乙腈/水(50/40/10,v / v / v)+ 0.1%甲酸+ 1 M甲酸铵。该方法在1–500 ng / mL的浓度范围内是线性的。该方法用于评估对比格犬(n = 5)三种不同剂量(0.1 mg / kg,0.3 mg / kg和1 mg / kg)的单次静脉内给药后Neurounina-1的药代动力学。静脉内施用0.1、0.3和1 mg / kg后,平均AUC _(0-tlast)值分别为26.10、115.81和257.28 ng〜(?)h / mL。观察到高达1.0 mg / kg的线性药代动力学。迅速消除了Neurounina-1,平均CL值分别为46.24、47.57和69.15 L / h,Vd为130.31、154.15和210.79 L,静脉内t_(1/2)为2.14、2.54和2.04 h剂量分别为0.1、0.3和1 mg / kg。这种新的分析方法可以快速测定一种新开发的化合物Neurounina-1,能够在低纳摩尔范围内发挥显着的神经保护作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号